With the collapse of Senate Republicans' efforts to repeal and replace the Patient Protection and Affordable Care Act (PPACA), President Donald Trump declared that his plan now was to “let Obamacare fail.”

An increasing trend of resistance to drugs that fight human immunodeficiency virus (HIV) could undermine global progress in treating and preventing the infection if early and effective action is not taken, warns the World Health Organization (WHO).

A new weapon in the arsenal of hepatitis C treatments seeks to help patients whose disease has so far resisted a cure, according to Gilead Sciences.

For the first time, researchers say that certain behaviors can prevent cognitive decline.

Value-based health care may be getting rave reviews in some places where it’s been tried but many hospital systems still cling to the fee-for-service system, Modern Healthcare reports.

Employers should do their best to accommodate workers with disabilities or who are recovering from injuries, but there’s been little change in the total unemployment numbers of such workers since the passage of the Americans With Disabilities Act in 1990, Workforce reports.

Health plans are pleased that, at least for now, the major gains in enrollment under Medicaid that the ACA facilitated will be left intact.

A phase 3 trial of an oral formulation of Paratek Pharmaceuticals’ antibiotic omadacycline has met its primary endpoints, FierceBiotech reports. The third late-phase success for omadacycline sets Paratek up to file for approval with the FDA, although incidence of vomiting and nausea cast a shadow over the data.

“Replace” seems to be out of the question at the moment, and things aren’t looking good for “repeal” either.

As researchers look for pain-relief solutions that don’t fuel the opioid epidemic, a new study of one contender appears to show that it has less potential for abuse and addiction.

The FDA has approved the first extended adjuvant therapy for early-stage, HER2-positive breast cancer. To further lower the risk of the cancer coming back, neratinib (Nerlynx, Puma Biotechnology Inc.) is indicated for adults who have previously been treated with a regimen that includes the drug trastuzumab (Herceptin, Genentech).

At least one health plan nudges the value-based payment system toward an approach that many experts believe has to happen if the scheme is to succeed. Most value-based payment systems reward doctors for keeping costs down, but don’t detract from their pay if costs go up.

For those of us who admit to needing a gossip fix now and then, this story aught to keep us satisfied for at least a year. It’s an old formula, though.

UnitedHealth Group’s net profit for the second quarter rose to $2.28 billion, or $2.32 a share, from $1.75 billion, or $1.81 a share, in last year’s second quarter, the Wall Street Journal reports. Profit from premiums rose from $36.4 billion to $39.4 billion, according to experts.

The FDA has turned down an application from Amgen and UCB to approve romosozumab (tentatively branded as Evenity) as a treatment for postmenopausal women with osteoporosis.